Product imageResearch use only

CAT. NO. DC86070Featured

304O13

Research highlights

Standard formulation lipidoid:cholesterol:DSPC:PEG molar ratio 50:38.5:10:1.5; PEG was optimized for 304O13 to 0.75 mol%.Optimized 304O13 LNP surface pKa 6.8, diameter 86.0 nm, zeta potential 13.7 mV and siRNA entrapment 84.2%.Optimized 304O13 gave an EC50 of 0.01 mg/kg siRNA for Factor VII silencing; a single 0.1 mg/kg dose kept Factor VII suppressed for 18 days.304O13 mediated CD45 silencing in peritoneal monocyte/macrophage populations and splenic dendritic cells and distributed Cy5.5-siRNA to liver and spleen.

Pack size & price

USD

Total$800

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

304O13 is a novel Biodegradable lipidoid for RNA delivery.

CAS No.	1566559-80-5
Chemical Name	304O13
Synonyms	β-Alanine, N ,N ′,N ′′-(nitrilotri-2,1-ethanediyl)tris[N -methyl-, 1,1′,1′′- tritridecyl ester (ACI);304O13, 304 O13
SMILES	O=C(OCCCCCCCCCCCCC)CCN(C)CCN(CCN(C)CCC(=O)OCCCCCCCCCCCCC)CCN(C)CCC(=O)OCCCCCCCCCCCCC
Formula	C57H116N4O6
M.Wt	951.54
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Whitehead KA, Dorkin JR, Vegas AJ, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nature Communications. 2014;5:4277.

Literature-reported formulation composition

Component	mol%	Role
304O13	50	Ionizable lipid
Cholesterol	38.5	Sterol
DSPC	10.75	Helper phospholipid
mPEG2000-DMG (paper MW 2660)	0.75	PEG lipid
Reported total	100	Source values retained

Formulation calculator unavailable. Calculator is enabled only for the explicitly reported molar formulation; the optimized 0.75 mol% PEG condition leaves 10.75 mol% DSPC by direct subtraction from the paper's 50:38.5:(11.5-X):X expression. No N/P is inferred. Obtain and verify the complete composition and component molecular weights before planning component quantities.

N/P ratioNot reported in the cited article

Total lipid:cargo weight ratio5:1 to 10:1 lipidoid:siRNA depending on experiment

Buffer & pH10 mM sodium citrate in the aqueous siRNA solution; post-mixing PBS dialysis. The article does not state a formulation pH for the citrate solution in the accessible Methods text.

CargoAnti-Factor VII siRNA, non-targeting siRNA control, CD45 siRNA and Cy5.5-labelled siRNA.

Administration routeIntravenous lateral tail-vein injection in female C57BL/6 mice.

DoseFactor VII efficacy screening at total siRNA dose 5 mg/kg; optimized dose response includes 0.1 mg/kg; biodistribution Cy5.5-siRNA at 1 mg/kg; cytokine/safety comparison at 3 mg/kg total siRNA.

Animal modelFemale C57BL/6 mice; liver hepatocytes, peritoneal monocyte/macrophage populations, splenic dendritic cells and other leukocyte subsets.

Formulation processEqual volumes of ethanol lipid solution and aqueous siRNA solution rapidly mixed by microfluidic device or pipet; diluted in PBS and dialyzed against PBS for 90 min in 3,500 MWCO cassettes.

Literature-reported performance for the cited formulation

Literature-reportedFactor VII silencingOptimized 304O13 LNP EC50 0.01 mg/kg siRNA; after one 0.1 mg/kg injection, Factor VII remained suppressed for 18 days.Optimized PEG condition, anti-FVII siRNA IV · Non-targeting siRNA controls and non-optimized PEG conditionsPDF p. 4, Fig. 3c-d.

Literature-reportedImmune-cell deliveryHigh CD45 silencing in CD11b+ monocyte/macrophage populations from peritoneal cavity and CD11c+ dendritic cells from spleen; peritoneal silencing up to approximately 90% and splenic silencing up to approximately 40% in the plotted results.304O13 CD45-siRNA LNP, 3 days post IV injection · Non-targeting siRNA LNPs and other lipidoidsPDF p. 4, Fig. 3e-f.

Literature-reportedBiodistributionAt 1 h, 304O13 Cy5.5-siRNA signal was primarily liver (42%) and spleen (24%), with 18% in kidneys; naked siRNA was 14% liver, 1% spleen and 71% kidneys.Cy5.5-siRNA, 1 mg/kg IV · Naked siRNAPDF p. 5, Fig. 4a-b.

Additional reported findings

Structure-function criteria

Across the library, O13 tail, at least three tails and a tertiary amine were associated with potent Factor VII silencing; surface pKa of at least approximately 5.5 was also required for strong activity. These are library-level findings, not a 304O13-only causal experiment.

· PDF pp. 6-7, Fig. 5 and Table 2.

Degradability

304O13 was hydrolyzed under acidic and basic conditions in the Methods; this demonstrates chemical degradability under the tested conditions and is not an in-vivo clearance half-life.

· PDF p. 8, Lipidoid hydrolysis Methods.

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetWhitehead KA, Dorkin JR, Vegas AJ, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nature Communications. 2014;5:4277. DOI: 10.1038/ncomms5277
All quantitative claims apply to the cited 304O13 LNP formulations and mouse assays, not to the neat lipid alone.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

No N/P was reported; none is calculated. The 10.75 mol% DSPC value is direct arithmetic from the paper's stated 11.5-X expression at X=0.75 and is labeled as a calculation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	10.5093 mL	2.1019 mL	1.0509 mL
25 mg	26.2732 mL	5.2546 mL	2.6273 mL
50 mg	52.5464 mL	10.5093 mL	5.2546 mL
100 mg	105.0928 mL	21.0186 mL	10.5093 mL
250 mg	262.7320 mL	52.5464 mL	26.2732 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

304O13

Pack size & price

Description & Application

Recommended Products

DLin-MC3-DMA

DLin-KC2-DMA

DODMA

DODAP

DMHAPC-Chol

503O13

L319

ATX-126(ATX-0126, lipid 10p)

Acuitas A9

C12-200